Back to top

Image: Bigstock

Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage

Read MoreHide Full Article

Sanofi’s (SNY - Free Report) global vaccines business unit Sanofi Pasteur and Translate Bio, Inc. (TBIO - Free Report) announced promising pre-clinical data on their coronavirus vaccine candidate MRT5500. Pre-clinical data demonstrated a favorable immune response profile against SARS-CoV-2 in mice and non-human primates.

The preclinical data showed that two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients.

The companies evaluated four dose levels — 0.2, 1, 5 and 10 µg per dose — of MRT5500 in mice and three dose levels — 15, 45 and 135 µg per dose — in non-human primates (NHPs). The vaccine has been developed as a two-administration vaccination schedule, three weeks apart.

Pre-clinical findings from the mice study showed that the candidate induced higher levels of binding antibodies and neutralizing antibodies specific to the SARS-CoV-2 spike protein with higher level of dose. First administration of MRT5500 achieved 100% seroconversion at all dose levels and a further increase in titers was observed following a second administration in the mice.

MRT5500 induced significantly higher levels of neutralizing antibody titers in NHPs compared to human convalescent sera by day 35. The candidate exhibited a Th1-biased T cell response against SARS-CoV-2 in both mice and NHPs.

These outcomes supported selection of the candidate for clinical development. A phase I/II study is planned for late 2020 to evaluate MRT550 in humans. Please note that Sanofi and Translate Bio have a collaboration agreement to develop novel mRNA vaccines, aimed at broadly addressing all current and future infectious diseases including COVID-19.

Shares of Sanofi have dipped 0.5% so far this year compared with the industry’s decrease of 0.9%.

Apart from MRT5500, Sanofi is developing another COVID-19 vaccine candidate in collaboration with Glaxo (GSK - Free Report) . Sanofi’s recombinant protein-based technology is being combined with Glaxo’s pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine. In September, a phase I/II study was initiated to evaluate their adjuvanted vaccine. Initial results from the study are expected in early December 2020. If phase I/II study data is favorable, the companies are likely to begin a pivotal phase III study before the end of this year.

Meanwhile, we note that there are other players in the coronavirus vaccine field with a few already in late-stage development. Leading coronavirus vaccine developers include Moderna (MRNA - Free Report) , Pfizer/BioNTech, AstraZeneca/Oxford University and J&J. Currently, Pfizer/BioNTech’s mRNA-based coronavirus vaccine candidate is leading the race with initial data from a late-stage study expected by the end of this month. Positive outcomes will likely support an emergency use authorization from the FDA.

Zacks Rank

Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Sanofi (SNY) - free report >>

Moderna, Inc. (MRNA) - free report >>

GlaxoSmithKline plc (GSK) - free report >>

Translate Bio, Inc. (TBIO) - free report >>